Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2007 3
2008 2
2010 1
2011 1
2013 1
2014 7
2015 7
2016 7
2017 3
2018 12
2019 7
2020 18
2021 18
2022 14
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR-Cas12-based detection of SARS-CoV-2.
Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, Miao X, Streithorst JA, Granados A, Sotomayor-Gonzalez A, Zorn K, Gopez A, Hsu E, Gu W, Miller S, Pan CY, Guevara H, Wadford DA, Chen JS, Chiu CY. Broughton JP, et al. Among authors: miao x. Nat Biotechnol. 2020 Jul;38(7):870-874. doi: 10.1038/s41587-020-0513-4. Epub 2020 Apr 16. Nat Biotechnol. 2020. PMID: 32300245 Free PMC article.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A, Hilder BW, Russell J, Infante J, Elsayed Y, Smit J, Goldberg JD. Girgis S, et al. Among authors: miao x. Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625. Blood Adv. 2023. PMID: 36006441 Free PMC article. No abstract available.
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Miao X, et al. Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15. Target Oncol. 2023. PMID: 37713090 Free PMC article.
Panoramic quality assessment tool for investigator initiated trials.
Lv W, Hu T, Jiang J, Qu T, Shen E, Duan J, Miao X, Zhang W, Qian B. Lv W, et al. Among authors: miao x. Front Public Health. 2022 Sep 13;10:988574. doi: 10.3389/fpubh.2022.988574. eCollection 2022. Front Public Health. 2022. PMID: 36176521 Free PMC article.
120 results